MD520Z - Метод постоперационного лечения пациентов с почечнокаменной болезнью - Google Patents
Метод постоперационного лечения пациентов с почечнокаменной болезнью Download PDFInfo
- Publication number
- MD520Z MD520Z MDS20110192A MDS20110192A MD520Z MD 520 Z MD520 Z MD 520Z MD S20110192 A MDS20110192 A MD S20110192A MD S20110192 A MDS20110192 A MD S20110192A MD 520 Z MD520 Z MD 520Z
- Authority
- MD
- Moldova
- Prior art keywords
- day
- days
- biomass
- extract
- cnm
- Prior art date
Links
- 230000002980 postoperative effect Effects 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims abstract description 11
- 206010029148 Nephrolithiasis Diseases 0.000 title abstract description 5
- 240000002900 Arthrospira platensis Species 0.000 claims abstract description 19
- 239000002028 Biomass Substances 0.000 claims abstract description 19
- 239000000284 extract Substances 0.000 claims abstract description 19
- 235000016425 Arthrospira platensis Nutrition 0.000 claims abstract description 18
- 230000001858 anti-Xa Effects 0.000 claims abstract description 10
- 229960005153 enoxaparin sodium Drugs 0.000 claims abstract description 9
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 claims abstract description 9
- 239000002775 capsule Substances 0.000 claims abstract description 6
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 4
- 238000001784 detoxification Methods 0.000 claims abstract description 4
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 3
- 230000002921 anti-spasmodic effect Effects 0.000 claims abstract description 3
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 3
- 238000001356 surgical procedure Methods 0.000 claims description 7
- 241000192700 Cyanobacteria Species 0.000 claims description 6
- 206010038478 Renal lithiasis Diseases 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 239000000812 cholinergic antagonist Substances 0.000 claims description 2
- 238000009160 phytotherapy Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 6
- 241001464430 Cyanobacterium Species 0.000 abstract description 4
- 208000000913 Kidney Calculi Diseases 0.000 abstract description 4
- 229940124575 antispasmodic agent Drugs 0.000 abstract 1
- -1 antispasmodics Substances 0.000 abstract 1
- 241000411851 herbal medicine Species 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000012273 nephrostomy Methods 0.000 description 5
- 238000007487 urography Methods 0.000 description 5
- 206010007027 Calculus urinary Diseases 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 208000008281 urolithiasis Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 206010037596 Pyelonephritis Diseases 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 229960004755 ceftriaxone Drugs 0.000 description 3
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 3
- 229960003405 ciprofloxacin Drugs 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000005084 renal tissue Anatomy 0.000 description 3
- 230000002784 sclerotic effect Effects 0.000 description 3
- 239000008279 sol Substances 0.000 description 3
- 208000019206 urinary tract infection Diseases 0.000 description 3
- UVITTYOJFDLOGI-UHFFFAOYSA-N (1,2,5-trimethyl-4-phenylpiperidin-4-yl) propanoate Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CC(C)N(C)CC1C UVITTYOJFDLOGI-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 229960004752 ketorolac Drugs 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 1
- 101000782236 Bothrops leucurus Thrombin-like enzyme leucurobin Proteins 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 208000000381 Familial Hypophosphatemia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000001663 anti-spastic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000010143 cystone Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- OMFNSKIUKYOYRG-MOSHPQCFSA-N drotaverine Chemical compound C1=C(OCC)C(OCC)=CC=C1\C=C/1C2=CC(OCC)=C(OCC)C=C2CCN\1 OMFNSKIUKYOYRG-MOSHPQCFSA-N 0.000 description 1
- 229960002065 drotaverine Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000010245 tubular reabsorption Effects 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к медицине, в частности к урологии и может быть использовано для постоперационного лечения пациентов с почечнокаменной болезнью.Согласно изобретению, заявленный метод включает применение антибиотиков, спазмолитических средств, антиоксидантов, дезинтоксикационную и фитотерапию, при этом с первого послеоперационного дня, дополнительно, внутримышечно вводят экстракт из биомассы штамма цианобактерии Spirulina platensis CNM - CB-02 в концентрации 0,5% - 1,0 мл, одновременно подкожно вводят эноксапарин натрия 2000 МЕ анти-Ха - 0,2 мл, в течение 10-и дней, после чего применяют экстракт из биомассы штамма цианобактерии Spirulina Platensis CNM - CB-02, по одной капсуле 5 мг, два раза в день, в течение 20-и дней.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20110192A MD520Z (ru) | 2011-12-06 | 2011-12-06 | Метод постоперационного лечения пациентов с почечнокаменной болезнью |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20110192A MD520Z (ru) | 2011-12-06 | 2011-12-06 | Метод постоперационного лечения пациентов с почечнокаменной болезнью |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD520Y MD520Y (en) | 2012-06-30 |
| MD520Z true MD520Z (ru) | 2013-01-31 |
Family
ID=46512861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20110192A MD520Z (ru) | 2011-12-06 | 2011-12-06 | Метод постоперационного лечения пациентов с почечнокаменной болезнью |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD520Z (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104435184A (zh) * | 2013-09-25 | 2015-03-25 | 廖国建 | 一种治疗肾结石的药物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1324669A1 (ru) * | 1985-12-30 | 1987-07-23 | Всесоюзный научно-исследовательский институт химии и технологии лекарственных средств | Средство дл лечени уролитиаза |
| SU1572625A1 (ru) * | 1987-12-28 | 1990-06-23 | Центральная Медико-Санитарная Часть N15 | Способ лечени уролитиаза |
-
2011
- 2011-12-06 MD MDS20110192A patent/MD520Z/ru not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1324669A1 (ru) * | 1985-12-30 | 1987-07-23 | Всесоюзный научно-исследовательский институт химии и технологии лекарственных средств | Средство дл лечени уролитиаза |
| SU1572625A1 (ru) * | 1987-12-28 | 1990-06-23 | Центральная Медико-Санитарная Часть N15 | Способ лечени уролитиаза |
Non-Patent Citations (1)
| Title |
|---|
| Protocolul naţional. Urolitiaza la adulţi. Chişinău, 2009, p-14-40, găsit în internet, < URL: http://www.ms.gov.md/_files/6157-PCN-88%2520UA.pdf>. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104435184A (zh) * | 2013-09-25 | 2015-03-25 | 廖国建 | 一种治疗肾结石的药物 |
Also Published As
| Publication number | Publication date |
|---|---|
| MD520Y (en) | 2012-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bradley et al. | Hematopoietic effect of Radix angelicae sinensis in a hemodialysis patient | |
| JP5809620B2 (ja) | 慢性前立腺炎、間質性膀胱炎及び／又は排尿障害の改善又は治療剤 | |
| DK2422793T3 (en) | Pharmaceutical compositions for dehydration, eutrophication and removal of the pathological tissues | |
| MD520Z (ru) | Метод постоперационного лечения пациентов с почечнокаменной болезнью | |
| RU2543344C2 (ru) | Способ лечения трофических язв | |
| Bailey et al. | Comparison of intermittent haemodialysis, prolonged intermittent renal replacement therapy and continuous renal replacement haemofiltration for lithium toxicity: a case report | |
| El-Agamy et al. | Protective role of panax gensing on fluvoxamine maleate induced structural changes in the submandibular salivary gland of rats | |
| Lemann Jr et al. | Kidney hematoma due to extracorporeal shock wave lithotripsy causing transient renin mediated hypertension | |
| CA2890120C (en) | Therapy for constipation | |
| CN102579528A (zh) | 一种防治前列腺疾病的药物组合物 | |
| CN100471508C (zh) | 一种治疗心脑血管疾病的药物及其制作方法 | |
| WO2019239963A1 (en) | Pharmaceutical composition for treating chronic constipation | |
| CN105147877A (zh) | 一种用于治疗甲沟炎的药物 | |
| CN101310757B (zh) | 一种治疗体癣及手足癣的药膏 | |
| CN112220860A (zh) | 一种尿毒症患者动静脉内瘘中药保护贴 | |
| Saunders | Nigella sativa dissolves small renal liths | |
| RU2185216C2 (ru) | Способ профилактики послеоперационных иммунодефицитов | |
| CN103893286A (zh) | 一种治疗慢性肾脏疾病的中药制剂及其制备方法 | |
| CN101181551B (zh) | 治疗痔疮的外用软膏 | |
| CN108403740A (zh) | 八宝丹及其制剂在制备治疗血精症的药物中的应用 | |
| RU2164797C1 (ru) | Способ лечения воспалительных заболеваний околоносовых пазух | |
| CN106983799A (zh) | 一种治疗中心静脉留置导管管口周围的肉芽组织增生的药物组合物 | |
| CN120267777A (zh) | 用于治疗或改善脑血栓的中药制剂 | |
| CN108498498B (zh) | 丹酚酸类成分在制备提高蛋白结合型尿毒素透析率及滤过率药物制剂中的应用 | |
| CN119792403A (zh) | 一种预防放射性口腔黏膜的壮药组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) | ||
| MM4Y | Short-term patent definitely lapsed due to non-payment of fees |